Opportunity Information: Apply for RFA DP 15 010
Apply for RFA DP 15 010
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Epidemiologic Study of Interstitial Cystitis" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.068 Chronic Diseases Research, Control, and Prevention.
- This funding opportunity was created on Feb 22, 2015 and posted on Dec 19, 2014.
- Applicants must submit their applications by Feb 24, 2015. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $600,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Hispanic serving InstitutionsHistorically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving InstitutionsNonprofits (Other than Institutions of Higher Education)Eligible Agencies of the Federal GovernmentU.S. Territory or Possession Faith based or Community based OrganizationsRegional OrganizationsBona Fide AgentsFederally Funded Research and Development Centers (FFRDCs)
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Epidemiologic Study of Interstitial Cystitis funding opportunity (RFA DP 15 010) is a CDC discretionary grant designed to support a large-scale epidemiologic research study focused on Interstitial Cystitis (IC) in adults. The central goal is to generate reliable, population-based estimates of how common IC is (prevalence) and how often new cases occur over time (incidence). Beyond basic frequency estimates, the CDC is looking for a study that can clearly describe who is affected by IC from a demographic standpoint and what the condition looks like clinically in real-world populations, including how it affects health and daily functioning when viewed at the population level rather than only through specialty clinics.
A major emphasis of the announcement is improving the public health understanding of IC by moving beyond fragmented or biased data sources. The study is expected to characterize IC across diverse adult populations and help clarify the condition s overall burden. This includes defining demographic and clinical characteristics, which typically means describing patterns by age, sex, race and ethnicity, geography, and other population factors, as well as symptom profiles, severity, comorbidities, health care use, and broader impacts on health. The intended output is practical: results should help improve how information is gathered about people living with IC, enable better identification of groups at higher risk, and support more informed clinical approaches and best practices.
In addition to the epidemiologic research itself, the FOA explicitly calls for the development and recommendation of a model for national surveillance of IC. In plain terms, the CDC is not only funding a one-time study, but also wants applicants to propose how the United States could monitor IC more consistently over time. A surveillance model would typically address workable case definitions for population monitoring, feasible data sources (such as surveys, health system data, or sentinel networks), methods to track trends, and approaches to ensure data are comparable across settings and time. The idea is to create a foundation for ongoing measurement, rather than leaving IC as a condition with limited standardized tracking at the national level.
This opportunity uses a cooperative agreement funding instrument, meaning the project is expected to involve substantial federal involvement and collaboration during the performance period, consistent with how CDC often manages complex public health research efforts. The CDC anticipates making one award. Total estimated funding for the opportunity is 3,000,000, with an award ceiling of 600,000 and an award floor of 300,000. There is no cost sharing or matching requirement. The activity category is health, and the CFDA number listed is 93.068 (Chronic Diseases Research, Control, and Prevention).
Eligibility is broad and includes a mix of higher education and community or research organizations, with explicit inclusion of Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, nonprofits other than institutions of higher education, eligible federal agencies, U.S. territories or possessions, faith-based or community-based organizations, regional organizations, bona fide agents, and Federally Funded Research and Development Centers. This range suggests CDC interest in strong scientific capacity paired with the ability to reach and represent diverse populations, which is often essential for credible prevalence and incidence estimation and for developing a surveillance approach that is equitable and nationally relevant.
Key administrative details include a posted date of December 19, 2014, with a closing date of February 24, 2015, and an archive date of March 26, 2015. The sponsoring agency is the Centers for Disease Control and Prevention. For assistance accessing the full announcement, CDC directed inquiries to the Technical Information Management Section (TIMS) within the Procurement and Grants Office, reachable at 770 488 2700 or PGOTIM@cdc.gov during standard business hours Eastern Time.
Overall, the grant is aimed at filling foundational public health gaps around Interstitial Cystitis by producing defensible national-level epidemiologic estimates, describing who is affected and how, quantifying the condition s health impact, and delivering a practical proposal for how IC could be monitored nationally going forward. The expected payoff is better targeting of interventions to populations at higher risk and stronger evidence to inform clinical best practices and health policy decisions tied to IC.
Frequently Asked Questions (FAQs): Epidemiologic Study of Interstitial Cystitis (RFA DP 15 010)
What is the Epidemiologic Study of Interstitial Cystitis funding opportunity?
This is a CDC discretionary grant opportunity (RFA DP 15 010) to support a large-scale epidemiologic research study focused on Interstitial Cystitis (IC) in adults.
What is the main purpose of this grant?
The central goal is to produce reliable, population-based estimates of how common IC is (prevalence) and how often new cases occur over time (incidence). The project is also expected to describe, at the population level, who is affected by IC and what the condition looks like clinically in real-world adult populations.
What specific outcomes is CDC looking for from the study?
Based on the announcement, CDC expects the study to deliver defensible national-level epidemiologic estimates (prevalence and incidence), describe demographic and clinical characteristics of adults with IC, and quantify how IC affects health and daily functioning when assessed across populations rather than only specialty clinic samples.
Why does the CDC emphasize population-based data rather than specialty clinic data?
The opportunity emphasizes improving public health understanding of IC by moving beyond fragmented or biased data sources. A population-based approach is intended to better represent diverse adult populations and provide estimates and descriptions that are more generalizable than those derived primarily from specialty clinics.
Who is the study focused on?
The study focus described in the opportunity is Interstitial Cystitis in adults.
What does the FOA say about characterizing who is affected by IC?
The FOA calls for clear demographic characterization, which typically includes patterns by age, sex, race and ethnicity, geography, and other population factors.
What does the FOA say about describing what IC looks like clinically in the population?
The opportunity indicates the study should describe IC clinically in real-world populations. Examples of clinical characterization mentioned include symptom profiles, severity, comorbidities, health care use, and broader impacts on health.
How is health impact expected to be addressed in this project?
The study is expected to describe how IC affects health and daily functioning at a population level and help clarify the overall burden of IC across diverse adult populations.
Is this funding only for a one-time epidemiologic study?
No. In addition to the epidemiologic research, the FOA explicitly calls for development and recommendation of a model for national surveillance of IC, with the goal of enabling more consistent monitoring over time.
What is meant by a "model for national surveillance" of IC in this opportunity?
In plain terms, CDC wants applicants to propose how the United States could monitor IC more consistently over time. The description notes that a surveillance model would typically address workable case definitions for population monitoring, feasible data sources (for example, surveys, health system data, or sentinel networks), methods to track trends, and approaches to ensure data are comparable across settings and time.
What type of funding mechanism is used for this opportunity?
This opportunity uses a cooperative agreement, which means substantial federal involvement and collaboration are expected during the performance period, consistent with how CDC manages complex public health research efforts.
How many awards does CDC anticipate making?
The CDC anticipates making one award.
How much funding is available under this opportunity?
The total estimated funding is 3,000,000. The award ceiling is 600,000 and the award floor is 300,000.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
What is the activity category for this grant?
The activity category listed is health.
What CFDA number is associated with this opportunity?
The CFDA number listed is 93.068 (Chronic Diseases Research, Control, and Prevention).
Who is eligible to apply?
Eligibility is broad and includes: Hispanic-serving Institutions; Historically Black Colleges and Universities; Tribally Controlled Colleges and Universities; Alaska Native and Native Hawaiian Serving Institutions; nonprofits other than institutions of higher education; eligible federal agencies; U.S. territories or possessions; faith-based or community-based organizations; regional organizations; bona fide agents; and Federally Funded Research and Development Centers. The opportunity also notes a mix of higher education and community or research organizations.
Why might eligibility be so broad for this program?
The description suggests CDC interest in pairing strong scientific capacity with the ability to reach and represent diverse populations, which is important for credible prevalence and incidence estimation and for developing a surveillance approach that is equitable and nationally relevant.
When was this funding opportunity posted and when was it due?
The posted date is December 19, 2014. The closing date is February 24, 2015.
When was the opportunity archived?
The archive date listed is March 26, 2015.
Which agency is sponsoring this opportunity?
The sponsoring agency is the Centers for Disease Control and Prevention (CDC).
Who should be contacted for help accessing the full announcement?
CDC directed inquiries to the Technical Information Management Section (TIMS) within the Procurement and Grants Office.
What contact information is provided for TIMS?
The phone number is 770-488-2700 and the email is PGOTIM@cdc.gov. The opportunity notes this is available during standard business hours Eastern Time.
What is the practical public health payoff CDC is aiming for?
The opportunity frames the payoff as filling foundational public health gaps around IC by producing defensible national-level estimates, describing who is affected and how, quantifying health impact, and delivering a practical proposal for national monitoring. The intended use of results includes improving how information is gathered about people living with IC, better identification of higher-risk groups, and supporting more informed clinical approaches and best practices.
Browse more opportunities from the same category: Health
Next opportunity: EBOLA HEALTHCARE PREPAREDNESS AND RESPONSE FOR SELECT CITIES WITH ENHANCED AIRPORT ENTRANCE SCREENINGS FROM AFFECTED COUNTRIES IN WEST AFRICA
Previous opportunity: ROSES 2014 Astrophysics Research and Analysis Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DP 15 010
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DP 15 010) also looked into and applied for these:
| Funding Opportunity |
|---|
| EBOLA HEALTHCARE PREPAREDNESS AND RESPONSE FOR SELECT CITIES WITH ENHANCED AIRPORT ENTRANCE SCREENINGS FROM AFFECTED COUNTRIES IN WEST AFRICA Apply for EP U3R 15 001 Funding Number: EP U3R 15 001 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: $1,000,000 |
| Using Longitudinal Data to Characterize the Natural History of Fragile X Syndrome to Improve Services and Outcomes Apply for RFA DD 15 003 Funding Number: RFA DD 15 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $350,000 |
| Alcohol Biosensors (STTR)(R41/R42) Apply for RFA AA 15 007 Funding Number: RFA AA 15 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Biosensors (SBIR)(R43/R44) Apply for RFA AA 15 008 Funding Number: RFA AA 15 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Grants for Preventing Violence and Violence Related Injury (R01) Apply for RFA CE 15 001 Funding Number: RFA CE 15 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $350,000 |
| Nuclear Organization and Function Interdisciplinary Consortium (NOFIC)(U54) Apply for RFA RM 14 030 Funding Number: RFA RM 14 030 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Public Health Research on Modifiable Risk Factors for Spina Bifida Apply for RFA DD 15 001 Funding Number: RFA DD 15 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $350,000 |
| Comparison and Validation of Screening Tools For Substance Use Among Pregnant Women Apply for RFA DP 15 003 Funding Number: RFA DP 15 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $600,000 |
| Evaluation of a Stepped Care Approach for Perinatal Depression Treatment in Obstetrics and GynecologyClinics Apply for RFA DP 15 005 Funding Number: RFA DP 15 005 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Cooperative Agreements to Support Comprehensive Medical Care for Thalassemia Apply for HRSA 15 079 Funding Number: HRSA 15 079 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Hemophilia Program Coordinating Center Apply for HRSA 15 087 Funding Number: HRSA 15 087 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Effectiveness of Teen Pregnancy Prevention Programs Designed Specifically for Young Males Apply for RFA DP 15 007 Funding Number: RFA DP 15 007 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Nurse Faculty Loan Program (NFLP) Apply for HRSA 15 049 Funding Number: HRSA 15 049 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Improving Surveillance and Prevention of Epilepsy Burden in US Communities Apply for RFA DP 15 009 Funding Number: RFA DP 15 009 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Population Based Birth Defects Surveillance and Utilization of Surveillance Data by Public Health Programs Apply for CDC RFA DD15 1508 Funding Number: CDC RFA DD15 1508 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Sentinel Enhanced Dengue Surveillance System (SEDSS) Sites to Evaluate the Epidemiology and Prevention of Dengue and other Acute Febrile Illnesses in Puerto Rico Apply for RFA CK 15 002 Funding Number: RFA CK 15 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $600,000 |
| Detection and Characterization of Emerging Vector Borne Zoonotic Apply for RFA CK 15 001 Funding Number: RFA CK 15 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $550,000 |
| Capacity Building to Prevent, Detect, and Respond to Emerging Infectious Disease Threats and Strengthen Global Health Security in Uganda Apply for RFA CK 15 003 Funding Number: RFA CK 15 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,500,000 |
| Continuing Prospective Birth Cohort Study Involving Environmental Uranium Exposure in the Navajo Nation Apply for RFA TS 13 0010501SUPP15 Funding Number: RFA TS 13 0010501SUPP15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $360,000 |
| Suicide Prevention Resource Center (SPRC) Apply for SM 15 003 Funding Number: SM 15 003 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $5,634,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DP 15 010", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.